share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Recursion Pharmaceuticals | 4：持股變動聲明
SEC announcement ·  04/03 17:44
Moomoo AI 已提取核心訊息
Dar Zavain, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock acquisition on April 1, 2024. The transaction involved a grant of 1,467 shares of Class A Common Stock at no cost. Following this transaction, Zavain's direct holdings in the company increased to a total of 89,056 shares. The grant is part of the company's stock-based compensation program and reflects the ongoing investment of key individuals in the company's success.
Dar Zavain, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock acquisition on April 1, 2024. The transaction involved a grant of 1,467 shares of Class A Common Stock at no cost. Following this transaction, Zavain's direct holdings in the company increased to a total of 89,056 shares. The grant is part of the company's stock-based compensation program and reflects the ongoing investment of key individuals in the company's success.
與 Recursion Pharmicals, Inc. [RXRX] 相關的達爾·扎瓦恩於 2024 年 4 月 1 日完成了股票收購。該交易涉及免費授予1,467股A類普通股。在這筆交易之後，Zavain在該公司的直接持股量增加到總計89,056股。該補助金是公司股票薪酬計劃的一部分，反映了關鍵人物對公司成功的持續投資。
與 Recursion Pharmicals, Inc. [RXRX] 相關的達爾·扎瓦恩於 2024 年 4 月 1 日完成了股票收購。該交易涉及免費授予1,467股A類普通股。在這筆交易之後，Zavain在該公司的直接持股量增加到總計89,056股。該補助金是公司股票薪酬計劃的一部分，反映了關鍵人物對公司成功的持續投資。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息